|Bid||70.750 x 0|
|Ask||70.950 x 0|
|Day's Range||69.950 - 71.300|
|52 Week Range||46.393 - 76.650|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.47 (0.66%)|
|1y Target Est||N/A|
SHANGHAI and SAN DIEGO, May 5, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of providing high quality biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Upon the closing of this acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical - the clinical CRO arm of WuXi AppTec - and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical's other clinical development services.
Revenue RMB2,769 Million , up 29.3% Net Profit Attributable to Owners of the Company RMB386 Million , up 33.0% Year-Over-Year Diluted EPS RMB0.33 , up 6.5% Year-Over-Year SHANGHAI , April 29, 2019 /PRNewswire/ ...
SHANGHAI, March 22, 2019 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 02359.HK), a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations, announces its audited annual results for the year ended December 31, 2018 today. All financials disclosed in this press release are prepared based on International Financial Reporting Standards (or "IFRS"). Gross profit grew 16.6% year-over-year to RMB3,777 million.
Stock code: 603259.SH/2359.HK) today announced the listing of approximately 116 million H-shares on the Main Board of the Hong Kong Stock Exchange. Based on the offer price of HK$68 per share, the net proceeds to be received by the Company are about HK$7,553 million (assuming the Over-allotment Option is not exercised). The Hong Kong IPO will be used to enhance the Company's capability and capacity worldwide.